{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:13:40Z","timestamp":1787912020067,"version":"build-2784847793"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hepatitis C virus (HCV) infection is a public health concern, with people living with opioid use disorder having a higher risk of infection. Despite the cooccurrence of HCV and opioid use disorder, little is known about the treatment patterns for the disorder in this population. This study characterized opioid agonist therapy adherence trajectories over 15 months following opioid agonist therapy initiation among people living with HCV and opioid use disorder and described the baseline characteristics of the patients within distinct opioid agonist therapy adherence trajectories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We used Merative MarketScan healthcare claims data from 2015 to 2019 to identify distinct medication treatment adherence trajectories via growth mixture modeling among 5,495 people who initiated opioid agonist therapy for opioid use disorder and were living with HCV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Our models identified three distinct opioid agonist therapy adherence trajectories over the 15 months of follow-up. We named these trajectories rapidly declining opioid agonist therapy adherence (class 1; N = 1,904; 35%), steadily declining opioid agonist therapy adherence (class 2; N = 2,150; 39%), and consistently high opioid agonist therapy adherence (N = 1,441; 26%). People in the consistently high adherence group were older, more likely to be women (vs. men), White (vs. Black), had HCV direct-acting antiviral treatment during the baseline period, and had the lowest prevalence of nonopioid substance use diagnoses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These results may inform support for populations with elevated baseline risk of low opioid agonist therapy adherence during follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ede.0000000000001895","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T08:00:46Z","timestamp":1751616046000},"page":"820-829","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Opioid Agonist Therapy Adherence Trajectories Among Commercially and Publicly Insured People Living With Hepatitis C in the United States"],"prefix":"10.1097","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8982-322X","authenticated-orcid":false,"given":"Catherine","family":"Psaras","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9067-1697","authenticated-orcid":false,"given":"Onyebuchi A.","family":"Arah","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA"},{"name":"Department of Statistics and Data Science, University of California, Los Angeles (UCLA), Los Angeles, CA"},{"name":"Practical Causal Inference Lab, University of California, Los Angeles (UCLA), Los Angeles, CA"},{"name":"Department of Public Health, Research Unit for Epidemiology, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara W.","family":"Chew","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Jae","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-3803","authenticated-orcid":false,"given":"Marjan","family":"Javanbakht","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-6169","authenticated-orcid":false,"given":"Roch A.","family":"Nianogo","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5792-3848","authenticated-orcid":false,"given":"Marissa J.","family":"Seamans","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"R1-20260511","doi-asserted-by":"crossref","first-page":"100052","DOI":"10.1016\/j.dadr.2022.100052","article-title":"What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size.","volume":"3","author":"Keyes","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"key":"R3-20260511","doi-asserted-by":"crossref","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder.","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R4-20260511","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.","volume":"95","author":"Samples","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"R5-20260511","doi-asserted-by":"crossref","first-page":"108062","DOI":"10.1016\/j.jsat.2020.108062","article-title":"Adherence to buprenorphine treatment guidelines among individuals with an opioid use disorder who have private insurance.","volume":"116","author":"Mark","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"R6-20260511","doi-asserted-by":"crossref","first-page":"e2334540","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl.","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R7-20260511","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine.","volume":"74","author":"Weinstein","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"R8-20260511"},{"key":"R9-20260511","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2023.3692","article-title":"A national hepatitis C elimination program in the United States: a historic opportunity.","volume":"329","author":"Fleurence","year":"2023","journal-title":"JAMA"},{"key":"R10-20260511","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jsat.2016.01.009","article-title":"Hepatitis C virus testing and treatment among persons receiving buprenorphine in an office-based program for opioid use disorders.","volume":"66","author":"Carey","year":"2016","journal-title":"J Subst Abuse Treat"},{"key":"R11-20260511","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000312","article-title":"High mortality among patients with opioid use disorder in a large healthcare system HHS public access.","volume":"11","author":"Hser","year":"2017","journal-title":"J Addict Med"},{"key":"R12-20260511","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/QAD.0000000000000642","article-title":"The causal effect of opioid substitution treatment on HAART medication refill adherence.","volume":"29","author":"Nosyk","year":"2015","journal-title":"AIDS"},{"key":"R13-20260511"},{"key":"R14-20260511","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"R15-20260511","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/jvh.13788","article-title":"Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the French health insurance claims databases using the ANRS CO22 HEPATHER cohort.","volume":"30","author":"Lam","year":"2023","journal-title":"J Viral Hepat"},{"key":"R16-20260511","first-page":"232","article-title":"Monitoring the hepatitis C care cascade using administrative claims data.","volume":"24","author":"Isenhour","year":"2018","journal-title":"Am J Manag Care"},{"key":"R17-20260511"},{"key":"R18-20260511","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in medicaid.","volume":"39","author":"Samples","year":"2020","journal-title":"Health Aff (Millwood)"},{"key":"R19-20260511","doi-asserted-by":"crossref","first-page":"108317","DOI":"10.1016\/j.drugalcdep.2020.108317","article-title":"Adherence to buprenorphine: an analysis of prescription drug monitoring program data.","volume":"216","author":"Pizzicato","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"R20-20260511","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.3390\/cancers15112943","article-title":"Adherence to opioid patient prescriber agreements at a safety net hospital.","volume":"15","author":"Pacheco","year":"2023","journal-title":"Cancers"},{"key":"R21-20260511","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jsat.2019.05.015","article-title":"A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: a view from the payer perspective.","volume":"104","author":"Kinsky","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"R22-20260511","year":"2021"},{"key":"R23-20260511","doi-asserted-by":"crossref","first-page":"100323","DOI":"10.1016\/j.alcr.2019.100323","article-title":"An overview of mixture modelling for latent evolutions in longitudinal data: modelling approaches, fit statistics and software.","volume":"43","author":"Van Der Nest","year":"2020","journal-title":"Adv Life Course Res"},{"key":"R24-20260511","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/aje\/kwad205","article-title":"Geographic variation, economic activity, and labor market characteristics in trajectories of suicide in the United States, 2008\u20132020.","volume":"193","author":"Keyes","year":"2024","journal-title":"Am J Epidemiol"},{"key":"R25-20260511","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/15248371003699969","article-title":"Twelve Frequently Asked Questions About Growth Curve Modeling.","volume":"11","author":"Curran","year":"2010","journal-title":"J Cogn Dev"},{"key":"R26-20260511","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1037\/tps0000176","article-title":"Ten frequently asked questions about latent class analysis.","volume":"4","author":"Nylund-Gibson","year":"2018","journal-title":"Transl Issues Psychol Sci"},{"key":"R27-20260511","first-page":"6","article-title":"Latent class growth analysis and growth mixture modeling using R: a tutorial for two R-packages and a comparison with mplus.","author":"Wardenaar","year":"2020","journal-title":"PsyArXiv"},{"key":"R28-20260511"},{"key":"R29-20260511","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v078.i02","article-title":"Estimation of extended mixed models using latent classes and latent processes: the R package lcmm.","volume":"78","author":"Proust-Lima","year":"2017","journal-title":"J Stat Softw"},{"key":"R30-20260511","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/epirev\/mxaa001","article-title":"Adherence to and retention in medications for opioid use disorder among adolescents and young adults.","volume":"42","author":"Viera","year":"2020","journal-title":"Epidemiol Rev"},{"key":"R31-20260511","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/add.13270","article-title":"Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization.","volume":"111","author":"Lo-Ciganic","year":"2016","journal-title":"Addiction"},{"key":"R32-20260511","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MLR.0000000000000727","article-title":"Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population.","volume":"55","author":"Saloner","year":"2017","journal-title":"Med Care"},{"key":"R33-20260511","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cpr.2013.07.007","article-title":"Drop-out from addiction treatment: a systematic review of risk factors.","volume":"33","author":"Brorson","year":"2013","journal-title":"Clin Psychol Rev"},{"key":"R34-20260511","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/10826084.2021.2023187","article-title":"The impact of a peer-navigator program on naloxone distribution and buprenorphine utilization in the emergency department.","volume":"57","author":"Ramdin","year":"2022","journal-title":"Subst Use Misuse"},{"key":"R35-20260511","doi-asserted-by":"crossref","first-page":"108065","DOI":"10.1016\/j.drugalcdep.2020.108065","article-title":"Strategies to improve treatment utilization for substance use disorders: a systematic review of intervention studies.","volume":"212","author":"Vogel","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"R36-20260511","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.drugalcdep.2011.03.024","article-title":"Gender differences in pharmacokinetics of maintenance dosed buprenorphine.","volume":"118","author":"Moody","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"R37-20260511","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/alcalc\/agac006","article-title":"A scoping review of gender, sex and sexuality differences in polysubstance use in adolescents and adults.","volume":"57","author":"Goodwin","year":"2022","journal-title":"Alcohol Alcohol (Oxford, Oxfordshire)"},{"key":"R38-20260511","doi-asserted-by":"crossref","first-page":"644","DOI":"10.15288\/jsad.2015.76.644","article-title":"The supply of physicians waivered to prescribe buprenorphine for opioid use disorders in the United States: a state-level analysis.","volume":"76","author":"Knudsen","year":"2015","journal-title":"J Stud Alcohol Drugs"},{"key":"R39-20260511","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2016.03.028","article-title":"Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City.","volume":"164","author":"Hansen","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"R40-20260511","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/add.15233","article-title":"African Americans now outpace whites in opioid-involved overdose deaths: a comparison of temporal trends from 1999 to 2018.","volume":"116","author":"Furr-Holden","year":"2021","journal-title":"Addiction (Abingdon, England)"},{"key":"R41-20260511","doi-asserted-by":"crossref","first-page":"e2214765","DOI":"10.1001\/jamanetworkopen.2022.14765","article-title":"Racial and ethnic disparities in buprenorphine and extended-release naltrexone filled prescriptions during the COVID-19 pandemic.","volume":"5","author":"Nguyen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R43-20260511","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.4088\/JCP.16m10657","article-title":"The 3-year course of multiple substance use disorders in the united states: a national longitudinal study.","volume":"78","author":"McCabe","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"R44-20260511","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00139709-200625020-00002","article-title":"Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences.","volume":"25","author":"M\u00e9garbane","year":"2006","journal-title":"Toxicol Rev"},{"key":"R45-20260511","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/add.13479","article-title":"Adopting the \u201ccascade of care\u201d framework: an opportunity to close the implementation gap in addiction care?","volume":"111","author":"Soc\u00edas","year":"2016","journal-title":"Addict Abingdon Engl"},{"key":"R46-20260511","doi-asserted-by":"crossref","first-page":"ofaa418","DOI":"10.1093\/ofid\/ofaa418","article-title":"The causal effect of opioid agonist treatment on adherence to direct-acting antiviral treatment for hepatitis C virus.","volume":"7","author":"Min","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"R47-20260511"},{"key":"R48-20260511","doi-asserted-by":"crossref","first-page":"e0194162","DOI":"10.1371\/journal.pone.0194162","article-title":"The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs.","volume":"13","author":"Ti","year":"2018","journal-title":"PLoS One"},{"key":"R49-20260511","doi-asserted-by":"crossref","first-page":"108569","DOI":"10.1016\/j.drugalcdep.2021.108569","article-title":"Patient, prescriber, and community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017\u201318.","volume":"221","author":"Stein","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"8 Suppl","key":"R50-20260511","first-page":"S131","article-title":"Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.","volume":"25","author":"Roebuck","year":"2019","journal-title":"Am J Manag Care"},{"key":"R51-20260511","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/cer.14.53","article-title":"Revisiting the washout period in the incident user study design: why 6\u201312 months may not be sufficient.","volume":"4","author":"Roberts","year":"2015","journal-title":"J Comp Eff Res"},{"key":"R52-20260511","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/pds.3922","article-title":"Controlling confounding of treatment effects in administrative data in the presence of time-varying baseline confounders.","volume":"25","author":"Gilbertson","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R53-20260511","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/EDE.0000000000001516","article-title":"Toward a clearer definition of selection bias when estimating causal effects.","volume":"33","author":"Lu","year":"2022","journal-title":"Epidemiology (Cambridge, Mass.)"},{"key":"R54-20260511","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1353\/obs.2016.0002","article-title":"Cohort restriction based on prior enrollment: examining potential biases in estimating cancer and mortality risk.","volume":"2","author":"Shortreed","year":"2016","journal-title":"Obs Stud"}],"container-title":["Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/EDE.0000000000001895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:00:20Z","timestamp":1778497220000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/EDE.0000000000001895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ede.0000000000001895","relation":{},"ISSN":["1044-3983","1531-5487"],"issn-type":[{"value":"1044-3983","type":"print"},{"value":"1531-5487","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]}}}